Diagnosis & Treatment Blogs

Read time: 4 minutes. Editor's Note: This article has been updated for 2025 as LUNGevity and ALCSI continue their partnership for Lung Cancer Awareness Month. Anyone with lungs can

Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug

On August 15, 2024, the US Food and Drug Administration (FDA) approved a new treatment regimen for people newly diagnosed with early-stage, resectable (able to be removed by

On August 19, 2024, the US Food and Drug Administration (FDA) approved a new treatment option for people newly diagnosed with locally advanced or metastatic non-small cell lung

Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are

Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming

Read time: 2 minutes. Many people have heard of HER2-positive breast cancer. But HER2 is an important biomarker found in many different types of cancer—including non-small cell

Read time: 3 minutes. Editors Note: If you missed the 2024 International Lung Cancer Survivorship Conference (ILCSC), make sure to join our email list and be the first to know when

Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with

Read time: 1 minute On June 13, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of repotrectinib (Augtyro™) to treat patients with advanced NTRK

Read time: 2 minutes The question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer

On May 16, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of tarlatamab-dlle (Imdelltra®) to treat patients with extensive stage small cell lung